Clinical trial populations are significantly less diverse than the actual population of the people the medicines are intended to treat. Though the life sciences industry acknowledges this lack of diversity in clinical trials, there has not been significant progress to address this important issue.

Technology investments and co-innovation with technology vendors will play a key role in enabling stakeholders to tackle the diversity challenge.

Everest Group’s 20+ page research report analyzes how all stakeholders can work together to increase diversity through appropriate metrics and governance mechanisms, diving into topics like:

• The current state of diversity in clinical trials
• Challenges with diversity initiatives today
• A technology framework to increase diversity in clinical trials
• Preparing a blueprint for success